Metformin, the world's most prescribed anti-diabetic drug, is also effective in preventing Type 2 diabetes in people at high risk, by lowering body weight, fat mass and circulating insulin levels through mechanisms that are incompletely understood.
of GDF15, which appears to be necessary for many of its actions as a metabolic chemopreventive agent.
Metformin has been used as a treatment for Type 2 diabetes since the 1950s (PMID: 28776081). More recent studies have shown that it can also prevent or delay the onset of Type 2 diabetes in people at high risk 1 2 .When compared to those receiving placebo, at-risk individuals treated with metformin manifest a modest but consistent reduction in body weight, lower circulating glucose and insulin levels and enhanced insulin sensitivity 3 . Although many mechanisms of action for the insulin sensitizing actions of metformin have been proposed 4 , few if any of these would explain the beneficial weight loss promoting effects of the drug which continue to be recognised 5 . A recent observational epidemiological study 6 noted a robust association of metformin use with circulating levels of GDF15, a peptide hormone produced by cells responding to a wide range of stressors 7 . GDF15 acts through a receptor complex solely expressed in the hindbrain, through which it suppress food intake [8] [9] [10] [11] . We hypothesized that metformin's effects to lower body weight and perhaps some of its other salutary effects in pre-diabetes might involve the elevation of circulating levels of GDF15.
We first measured circulating GDF15 levels at 6, 12 and 18 months in all available participants from the CAMERA clinical trial 12 , a randomized placebo-control trial of metformin in people without diabetes but with a history of cardiovascular disease. In this study, metformin treated participants were reported to lose ~3.5% of starting body weight with no significant change in weight in the placebo arm 12 . Metformin treatment was associated with significantly (p < 0.001) increased levels of circulating GDF15 at all three time points relative to placebo (Fig 1A) .
Furthermore, the change in serum GDF15 from baseline in metformin recipients was significantly correlated (r=-0.26, p=0.024) with the amount of weight loss (Fig 1B) .
To determine if metformin treatment increased serum GDF15 levels in mice, we administered metformin to high fat fed mice by oral gavage and measured serum GDF15 levels. A single dose of 300 mg/kg of metformin increased GDF15 levels for at least 8 hours (Fig 1C) . A higher dose of metformin, 600 mg/kg, increased serum GDF15 levels 4-6 fold at 4 and 8-hours postdose, which were sustained over vehicle-treated mice for 24 hours. The effects of metformin on circulating GDF15 levels in lean, chow-fed mice were less pronounced ( Supplementary   Fig 1) suggesting an interaction between metformin and the high fat fed state.
In order to examine the extent to which the elevation in circulating GDF-15 induced by metformin is responsible for its effects on body weight, Gdf15 +/+ and Gdf15 -/mice switched from chow to a high fat diet were dosed with metformin. High fat feeding induced similar weight gain in mice of both genotypes (Fig 2A) . Metformin (300mg/kg/day), delivered by oral gavage starting 3 days after switching the diets, and maintained for 11 days, completely prevented diet-induced weight gain in Gdf15 +/+ mice but had no effect in Gdf15 -/mice (Fig 2A) . In this study metformin significantly reduced cumulative food intake in wild type mice but this effect was abolished in Gdf15 -/mice (Fig 2B) . The identical protocol was applied to mice lacking GFRAL, the ligand-binding component of the hindbrain-expressed GDF15 receptor complex.
Consistent with the results in mice lacking GDF15, metformin was unable to prevent weight gain in Gfral -/mice (Fig 2C) , despite similar levels of serum GDF15 ( Supplementary Fig 2A   & B) . However, in this experiment, the reduction in cumulative food intake did not reach statistical significance (Supplementary 2C).
To investigate the contribution of GDF15/GFRAL signalling to sustained, metformindependent weight regulation, we performed a 9-week study in which mice received approximately 250-300 mg/kg/day of metformin that was incorporated into their high-fat diet.
The mice lost approximately 10% body weight after 1 month on this diet (Fig 2D) . At this time, we started dosing mice with an anti-GFRAL antagonist antibody, with a single dose administered every week. Metformin-consuming mice treated with anti-GFRAL gained ~12% body weight after 5 weeks, while IgG control treated mice maintained a steady weight 10% below their starting weight (Fig 2D) . The weight gain in anti-GFRAL treated mice was exclusively from increased fat mass (Supplementary Fig 2D) .
While GDF15 dependent effects on suppression of food intake clearly contributes to the weight loss seen with recombinant GDF15 [8] [9] [10] [11] and with metformin, we undertook experiments to see if there were additional effects on energy expenditure by undertaking indirect calorimetry in metformin-and placebo-treated mice treated with anti-GFRAL antibody. All data were analysed by ANCOVA with body weight as the co-variate. Metformin treatment resulted in a statistically significant increase in metabolic rate which was blocked by antagonism of GFRAL (Fig 2E) . We conclude that, under conditions where GDF15 levels are increased by metformin, body weight reduction is contributed to by both reduced food intake and an inappropriately high energy expenditure.
To examine the extent to which the insulin sensitising effects of metformin are dependent on GDF15 we repeated the experiment described in Fig 2A (see Supplementary Fig 3) , this time undertaking insulin tolerance testing in metformin and sham-treated GDF15 null mice and their wild type littermates after 11 days of high fat feeding. In wild type mice, metformin significantly increased insulin sensitivity as assessed by the area under the plasma glucose curve at an ITT (Fig 3A) . This effect was abolished in mice lacking GDF15.
Both fasting blood glucose and fasting insulin were reduced by metformin with the effect of metformin being modulated by the presence or absence of GDF15. Metformin significantly (p<0.05) reduced mean fasting insulin by 60 % in wild type mice with a non-significant 33% reduction seen in mice lacking GDF15 (Fig 3B, 3C) .
To establish which tissues were responsible for the rise in circulating GDF15 after metformin administration we examined gene expression in a tissue panel obtained from mice fed a high fat diet (for 4 weeks) and sacrificed 6 hours after a single gavage dose of metformin (600mg/kg). Circulating concentrations of GDF15 increased ~4-fold compared to sham treated mice ( Supplementary Fig 4) . Gdf15 mRNA was significantly increased by metformin in small intestine, colon and kidney after 6 hours, but not in skeletal muscle or adipose tissue ( Fig 4A) .
In situ hybridisation studies demonstrated strong Gdf15 expression in crypt enterocytes in the colon and small intestine and in periglomerular renal tubular cells. (Fig 4B, Supplementary   Fig 5) . We confirmed these sites of tissue expression in a separate cohort of HFD fed mice (those used in Fig 2A) , treated with metformin for 11 days (Supplementary Fig 6) .
Further, in human ( Fig 4C) and murine (Fig 4D) intestinal-derived organoids grown in 2D transwells and treated with metformin, we saw a significant induction of mRNA expression and GDF15 protein secretion.
Given the proposed importance of the liver for metformin metabolic action it was notable that GDF15 levels were only increased in the liver of a single mouse ( Fig 4A) . To test whether hepatocytes are capable of responding to biguanide drugs with an increase in GDF15 we incubated freshly isolated murine hepatocytes ( Supplementary Fig 7A) and stem-cell derived human hepatocytes ( Supplementary Fig 7B) with metformin and found a clear induction of GDF15 expression. Additionally, acute administration of the more cell penetrant biguanide drug phenformin to mice significantly increased circulating GDF15 levels ( 7C) and markedly increased Gdf15 mRNA expression in hepatocytes in a predominantly peri-central pattern (Supplementary Fig 7D&E) .
Supplementary Fig
GDF15 expression has been reported to be a downstream target of the cellular integrated stress response (ISR) pathway [13] [14] [15] .Gdf15 mRNA levels were increased in kidney and colon 24 h after a single oral dose of metformin and these changes correlated positively with the fold elevation of CHOP mRNA (Fig 5 A&B) . As phenformin has broader cell permeability than metformin 16 we used it to explore the effects of biguanides on the ISR and its relationship to GDF15 expression in vitro. In murine embryonic fibroblasts (MEFs), which do not express the organic cation transporters needed for the uptake of metformin, phenformin (but not metformin) increased EIF2α phosphorylation, ATF4 and CHOP expression, ( Fig 5C) and GDF15 mRNA (Fig 5D) , though the changes in EIF2a phosphorylation and ATF4 and CHOP expression were modest compared with those induced by tunicamycin despite similar levels of GDF15 mRNA induction. Both genetic deletion of ATF4 and siRNA-mediated knockdown of CHOP in MEFs significantly reduced phenformin-mediated induction of GDF15 mRNA expression (Fig 5E and 5F) . In addition, phenformin induction of GDF15 was markedly reduced by co-treatment with the EIF2α inhibitor, ISRIB but, notably, not by the PERK inhibitor, GSK2606414 (Fig 5G) . Further, GDF15 secretion in response to metformin in murine duodenal organoids was also significantly reduced by co-treatment with ISRIB ( Fig 5H) .
However, gut organoids derived from CHOP null mice are still able to increase GDF15 secretion in response to metformin (Fig 5I) indicating the existence of CHOP-independent pathways under some circumstances. The data suggest that the effects of biguanides on GDF15 expression are at least partly dependent on the ISR pathway but are independent of PERK. However, the relative importance of components of the ISR pathway may vary depending on specific cell type, dose and agent used.
Our observations represent a significant advance in our understanding of pleiotropic actions of metformin, one of the world's most frequently prescribed drugs. Metformin has recently been shown to increase circulating GLP1 levels [17] [18] [19] , but its metabolic effects in mice are unimpaired in mice lacking the GLP-1 receptor 20 . Metformin has also been reported to alter the intestinal microbiome 21, 22 but it is challenging to design experiments to firmly establish the causal relationship of that change to the beneficial effects of the drug 23 .
In the work presented herein, we describe a body of data from humans, cells, organoids and mice that securely establish a role for GDF15 in the mediation of metformin's effects in the pre-diabetic state. Future studies will explore the extent to which the GDF15 dependent effects on circulating insulin and insulin sensitivity are mediated by its effects on energy balance or whether GDF15 has additional independent metabolic actions. The extent to which metformin's glucose lowering actions in Type 2 diabetes are mediated by GDF15 will also require additional study.
It is notable that the lower small intestine and colon are a major site of metformin induced GDF15 expression. A body of work is emerging which strongly implicates the intestine as a major site of metformin action, with metformin being demonstrated to cause increased glucose uptake into colonic epithelium from the circulation 24 and with a gut-restricted formulation of metformin showing enhanced glucose lowering efficacy over formulations which are systemically absorbed 25 .Our finding that the intestine is a major site of metformininduced GDF15 expression provides a further mechanism through which metformin action on the intestinal epithelium may mediate a substantial proportion of its beneficial metabolic effects.
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Methods

Human Studies
CAMERA was a randomized, double-blinded, placebo-controlled trial designed to investigate the effect of metformin on surrogate markers of cardiovascular disease in patients without diabetes, aged 35 to 75, with established coronary heart disease and a large waist circumference (≥ 94cm in men, ≥80 cm in women) (NCT00723307). This single-centre trial enrolled 173 adults who were followed up for 18 months each. A detailed description of the trial and its results has been published previously 12 . In brief, participants were randomized 1:1 to 850mg metformin or matched placebo twice daily with meals. Participants attended six monthly visits after overnight fasts and before taking their morning dose of metformin. Blood 
Mouse Studies
Studies were carried out in two sites; NGM Biopharmaceuticals, California, USA and Sample sizes were determined on the basis of homogeneity and consistency of characteristics in the selected models and were sufficient to detect statistically significant differences in body weight, food intake and serum parameters between groups. Experiments were performed with animals of a single gender in each study. Animals were randomized into the treatment groups based on body weight such that the mean body weights of each group were as close to each other as possible, but without using excess number of animals.
No samples or animals were excluded from analyses. Researchers were not blinded to group allocations.
Mouse study 1. Acute two-dose metformin study in high fat diet fed mice.
Single housed male mice fed 60% HFD were used. Metformin (Sigma-Aldrich # 1396309) was reconstituted in water at 30 mg/ml for oral gavage and given in early part of light cycle.
Terminal blood was collected by cardiac puncture into EDTA-coated tubes. GDF15 levels were measured using Mouse/Rat GDF15 Quantikine ELISA Kit (Cat#: MGD-150, R&D Systems, Minneapolis, MN) according to the manufacturers' instructions. RNA was isolated from tissues using the Qiagen RNeasy Kit. RNA was quantified and 500ng was used for cDNA synthesis (SuperScript VILO 11754050 ThermoFisher) followed by qPCR. All Taqman probes were purchased from Applied Biosystems. All genes are expressed relative to 18s control probe and were run in triplicate.
Mouse study 2. Acute metformin study in chow fed animals.
2.i) ad libitum group.
Male C57BL6/J mice (Charles River, Margate, UK) were studied at 11 weeks old. 500mg of metformin was dissolved in 20 mls of water to make a working stock of 25mg/ml. 1 hr after onset of light cycle mice received a single dose by oral gavage of either metformin at 300mg/kg dose (Sigma, PHR1084-500MG) or matched volume of sham (water). Weight (mean± SEM) of control and treatment groups were 27.2 ± 0.3 vs 26.7 ± 0.2 g, respectively on day of study. After gavage mice were returned to an individual cage and were sacrificed at relevant time point by terminal anaesthesia (Euthatal by Intraperitoneal injection). Blood was collected into Sarstedt Serum Gel 1.1ml Micro Tube, left for 30mins at room temperature, spun for 5mins at 10k at 4 0 C before being frozen and stored at -80 o C until assayed. Mouse GDF15 levels were measured using a Mouse GDF15 DuoSet ELISA (R&D Systems) which had been modified to run as an electrochemiluminescence assay on the Meso Scale Discovery assay platform.
2.ii) fasted group.
Mice, conditions and methods as in (2.i) except male mice studied at 9 weeks old and that with no food in hopper. Weight (mean± SEM) of groups at gavage were 22.3±0.5 g and 23.2±0.7g for control and treatment groups, respectively. Experimental cohorts of male Gdf15 -/and wild type mice were generated by het x het breeding pairs. Mice were aged between 4.5 and 6.5 months. Body weight of study groups (mean±SEM) were 38.2±1.0g; 38.8±0.6g for wild type sham and metformin treatment respectively, and 37.9±0.8g; 37.0±1.4g for Gdf15 -/sham and metformin treatment respectively. One week prior to study start mice were single housed and 3 days prior to first dose of metformin treatment, mice were transferred from standard chow to 60% high fat diet.
Mouse study 3. Metformin to high fat diet fed
Each mouse received a daily gavage of either sham or metformin for 11 days, and their body weight and food intake measured daily in the early part of the light cycle. One data point of 25 food intake points collected on day11 of study was lost due to technical error (mouse;
Gdf15 +/+ metformin). On day 11 mice were sacrificed by terminal anaesthesia 4 hours post gavage, blood was obtained as in study 2. Tissues were fresh frozen on dry ice and kept at -80 0 C until day of RNA extraction.
Mouse study 4. Metformin to high fat diet fed Gfral -/mice.
Gfral -/mice were purchased from Taconic (#TF3754) on a mixed 129/SvEv-C57BL/6 background and backcrossed for 10 generations to >99% C57BL/6 background at NGM's animal facility. Experimental cohorts were generated by het X het breeding pairs. Study design as Study 3, except terminal blood was collected into EDTA-coated tubes. Male C57BL6/J mice aged 14 weeks with supplier, protocol and methods as study 2, except phenformin (Sigma PHR1573-500mg) used instead of metformin.
Organoid studies.
Duodenal and ileal mouse organoid line generation, maintenance and 2D culture was performed as previously described 30 . CHOP null mice were kind gift of Dr Jane Goodall Research Ethics Committee under license number 09/H0308/24) were generated from fresh surgical specimens (Tissue Bank Addenbrooke's Hospital (Cambridge, UK)) following a modified protocol 30, 31 . Briefly rectal tissue was chopped into 5mm fragments and incubated in 30 mM EDTA for 3x10mins, with tissue shaken in PBS after each EDTA treatment to release intestinal crypts. The isolated crypts were then further digested using TrypLE (Life Technologies) for 5 mins at 37⁰C to generate small cell clusters. These were then seeded into basement membrane extract (BME, R&D technology), with 20 μl domes polymerised in multiwell (48) dishes for 30-60 mins at 37⁰C. Organoid medium (Sato et al 2011) was then overlaid and changed 3 times per week. Human organoids were passaged every 14-21 days using TrypLE digestion for 15 mins at 37⁰C, followed by mechanical shearing with rigorous pipetting to breakup organoids into small clusters which were then seeded as before in BME.
For transwell experiments TrypLE digested organoids were seeded onto matrigel (Corning) coated (2% for 60 mins at 37⁰C) polyethylene Terephthalate cell culture inserts, pore size 0.3 μm (Falcon) in organoid medium supplemented with Y-27632 (R&D technology). Organoids were observed through the transparent cell inserts to ensure 2D culture formation (allowing apical cell access for drug treatments). Medium was changed after 2 days and then switched on day 3 to a differentiation medium with wnt3A conditioned medium reduced to 10% and SB202190 / nicotinamide omitted from culture for 5 days.
For GDF 15 secretion experiments 2D cultured organoid cells were treated for 24 hrs with indicated drugs, with medium then collected and GDF15 measured at the Core Biochemical Assay Laboratory (Cambridge) using the human or mouse GDF15 assay kit as outlined in CAMERA human study and mouse study 2 above.
RNA was extracted using TRI reagent (Sigma), with any contaminated DNA eliminated using DNA free removal kit (Invitrogen). Purified RNA was then reverse transcribed using superscript II (Invitrogen) as per manufacturer's protocol. RT-qPCR was performed on a QuantStudio 7 (Applied Biosystems) using Fast Taqman mastermix and the following probes (Applied Biosystems); Human GDF15 (Hs00171132_m1), Human ACTB (Hs01060665_g1). Gene expression was measured relative to β-actin in the same sample using the ΔCt method, with fold (cf. control) shown for each experiment.
Hepatocyte studies
Primary mouse hepatocyte isolation and culture.
Hepatocytes from 8-12 week old C57B6J male mice were isolated by retrograde, nonrecirculating in situ collagenase liver perfusion. In brief: livers were perfused with modified Hanks medium without calcium (NaCl-8.0 g/L; KCl-0.4 g/L; MgSO4.7H2O-0.2 g/L;
Na2HPO4.2H2O-0.12 g/L; KH2PO4-0.12 g/L; Hepes-3 g/L; EGTA-0.342 g/L; BSA-0.05 g/L) followed by digestion with perfusion media supplemented with calcium (CaCl2.2H2O-0.585 g/L) and 0.5mg/ml of collagenase IV (Sigma, C5138). The digested liver was removed and washed using chilled DMEM:F12 (Sigma) medium containing 2 mM L-glutamine, 10 % FBS, 1% penicillin/streptomycin (Invitrogen). Viable cells were harvested by Percoll (Sigma) gradient. The final pellet was resuspended in the same DMEM:F12 media. Cell viability was greater than 90%. Hepatocytes were plated onto primaria plates (Corning). Hepatocytes were allowed to recover and attach for 4-6 hr before replacement of the medium overnight prior to stress treatments the following day for the times and concentrations indicated.
Generation and culture of iPSC derived human hepatocytes.
The human induced pluripotent cell (hiPSC) line A1ATD R/R used in this work was derived as previously described 32, 33 , under approval by the regional research ethics committee (reference number 08/H0311/201). hiPSCs were maintained in Essential 8 chemically defined media 34 3 supplemented with 2ng/ml Tgf-ß (R&D) and 25ng/ml FGF2 (R&D), and cultured on plates coated with 10µg/ml Vitronectin XF TM (STEMCELL Technologies). Colonies were regularly passaged by short-term incubation with 0.5mM EDTA in PBS. For hepatocyte differentiation, colonies were dissociated into single cells following incubation with StemPro™ Accutase™ Cell Dissociation Reagent (Gibco) for 5 minutes at 37°C. Single cell suspensions were seeded on plates coated with 10µg/ml Vitronectin XF TM (STEMCELL Technologies) in maintenance media supplemented with 10µM ROCK Inhibitor Y-27632 (Selleckchem) and grown for up to 72h prior to differentiation. Hepatocytes were differentiated as previously reported 35 , with minor modifications as listed. Briefly, following endoderm differentiation, anterior foregut specification was achieved after 5 days of culture with RPMI-B27 differentiation media supplemented with 50ng/ml Activin A (R&D) 35 . Foregut cells were further differentiated into hepatocytes with HepatoZYME-SFM (Gibco) supplemented with 2mM L-glutamine (Gibco), 1% penicillin-streptomycin (Gibco), 2% non-essential amino acids (Gibco), 2% chemically defined lipids (Gibco), 14μg/ml of insulin (Roche), 30μg/ml of transferrin (Roche), 50 ng/ml hepatocyte growth factor (R&D), and 20 ng/ml oncostatin M (R&D), for up to 27 days.
Cellular studies on integrated stress response
Chemicals and Reagents
Tunicamycin and ISRIB were purchased from Sigma-Aldrich. Metformin and Phenformin was purchased from Cayman Chemicals and GSK2606414 from Calbiochem. The antibody for GDF15 and CHOP (sc-7351) were obtained from Santa Cruz. Phospho S51 EIF2 (ab32157) and Calnexin (ab75801) were purchased from Abcam. The antibody for ATF4 was a kind gift from Dr David Ron (CIMR, Cambridge).
Eukaryotic cell lines and treatments
Mouse embryonic fibroblast (MEF) cells lines were obtained from David Ron (CIMR/IMS, Cambridge) and maintained as previously described 15 . MEFs were transfected with 30 nM control siRNA or a smartpool on-target plus siRNA for mouse CHOP (Dharmacon -L-062068-00-0005) using Lipofectamine RNAi MAX (Invitrogen) according to the manufacturer's instruction. 48 h post siRNA transfection, cells were processed for RNA and protein expression analysis. All cells were maintained at 37 °C in a humidified atmosphere of 5 % CO2 and seeded onto 6-or 12-well plates prior to stress treatments for the times and concentrations indicated. Vehicle treatments (e.g. DMSO) were used for control cells when appropriate. 
RNA isolation/cDNA synthesis/Q-PCR
Figures legends
Figure 1. Effect of Metformin on circulating GDF15 levels in humans and mice
A) Plasma GDF15 concentration (mean± SEM) in overweight or obese non-diabetic participants with known cardiovascular disease randomised to metformin (n range =86) vs placebo (n range =85).
B)
Association between change in body weight and change in GDF15 among metformin treated participants (n=74, r=-0.26, p=0.024). Grey area is 95% confidence interval for slope.
C) Serum GDF15 levels in obese mice measured 2, 4, 8 or 24 hours after a single oral dose of 300 mg/kg or 600 mg/kg metformin. Data are mean ± SEM (n=7/group); P by 2-way ANOVA with Tukey's correction for multiple comparisons. C) Percentage change in body weight of Gfral +/+ and Gfral -/mice on a high-fat diet treated with metformin (300mg/kg/day) for 11 days. Data are mean ± SEM, n=6 all groups);P by 2-way ANOVA with Tukey's correction for multiple comparisons.
D)
Percentage change in body weight of metformin-treated obese mice dosed with an anti-GFRAL antagonist antibody, weekly for 5 weeks (yellow), starting 4 weeks after initial metformin exposure (grey). Data are mean ± SEM (n=7 Veh + control IgG and Metformin + anti -GFRAL; n=8 other groups); P by 2-way ANOVA with Tukey's correction for multiple comparisons. "calo" = period in which energy expenditure measured( see Figure 2E ). E) Scatter plot of ANCOVA analysis of energy expenditure against body weight of mice treated with anti-GFRAL or control IgG (mice as in Figure 2D ) 7 weeks after starting metformin, n=6 mice/group. Data are individual mice and P for metformin calculated using ANCOVA with body weight as a covariate and treatment as a fixed factor.
Supplementary Figure 2. Response of high fat diet fed Gdf15 -/and Gfral -/mice to metformin.
A) Circulating GDF15 levels in high fat diet fed Gdf15 +/+ and Gdf15 -/mice given oral dose of metformin ( 300mg/kg) once daily for 11 days. Samples were collected 4 hours after the final oral dose of metformin .Data are mean ± SEM, mice as in Figure 2 A. All samples from Gdf15 -/were below lower limit of assay (< 2pg/ml), P by two-tailed t-test.
B) Circulating GDF15 levels in high fat diet fed Gfral +/+ and Gfral -/mice given oral dose of metformin ( 300mg/kg) once daily for 11 days. Samples were collected 4 hours after the final oral dose of metformin. Data are mean ± SEM, mice as in Figure 2C , P by 2-way ANOVA with Tukey's correction for multiple comparisons.
C) Cumulative food intake in high fat diet fed Gfral +/+ and Gfral -/mice on a high fat diet given oral dose of metformin (300mg/kg) once daily for 11 days . Data are mean ± SEM, mice as in Figure 2C .
D)
Fat and lean mass in metformin-treated obese mice dosed with an anti-GFRAL antagonist antibody, weekly for 5 weeks, starting 4 weeks after initial metformin exposure (mice as Figure 2D ). Body composition was measured using MRI after 4 weeks of metformin exposure, prior to receiving anti-GFRAL (week 4), after 6 weeks of metformin exposure and 2 weeks after receiving anti-GFRAL (week 6) and after 9 weeks of metformin exposure and 5 weeks after receiving anti-GFRAL (week 9).
Data are mean ± SEM (n=7 Veh + control IgG and Metformin + anti -GFRAL; n=8 other groups); P by 2-way ANOVA with Sidak's correction for multiple comparisons. Figure 3 . Response of second, independent cohort of high-fat diet fed Gdf15 +/+ and Gdf15 -/mice to metformin.
Supplementary
A) Percentage change in body weight and B) cumulative food intake in Gdf15 +/+ and Gdf15 -/mice on a high-fat diet treated with metformin (300mg/kg/day) for 11 days. Data are mean ± SEM (n=6/group, except Gdf15 -/-sham= 8); P by 2-way ANOVA with Tukey's correction for multiple comparisons. Analysis of Gdf15 mRNA expression in tissues collected from high-fat fed wild type mice 6 hrs after single dose of oral metformin (600mg/kg). Data are mean ± SEM, n=7/group. A) mRNA analysis of fresh frozen tissue normalised to expression levels of ActB.P by two tailed t-test. B) In situ hybridization for Gdf15 mRNA (red spots; n= 7 per group, representative images from the mouse with plasma GDF15 closest to group median). C) Gdf15 mRNA expression (left) and GDF15 protein in supernatant (right) of human derived 2D monolayer rectal organoids treated with metformin. Each colour represents independent experiments (n= 4), data are mean ± SEM, P by two-tailed ttest. D) GDF15 protein in supernatants of mouse-derived 2D monolayer duodenal (left) and ileal (right) organoids treated with metformin. Each colour represents independent experiment (duodenal n= 5, ileal n=3), data are mean ± SEM, P by twotailed t-test.
Supplementary Figure 5 . In situ hybridization for Gdf15 mRNA expression (red spots) in all colons examined collected from high-fat fed wild type mice, 6 hrs after single dose of oral metformin (600mg/kg)( right side) or sham gavage ( left side), n=7/group, mice as Figure 4 .
Supplementary Figure 6 . Analysis of Gdf15 mRNA expression in tissue from high fat diet fed Gdf15 +/+ mice given oral dose of metformin (300mg/kg) once daily for 11 days , normalised to expression levels of ActB ( see Figure 2A) . Data are mean ± SEM, n=6 metformin, n=7 sham, P by two tailed t-test. with Phen for a further 6 h. mRNA expression is presented as fold-expression relative to its respective control treatment (set at 1) or phen treated samples (set as 100) with normalisation to HPRT gene expression. Data is expressed as mean ± SEM from two for (D) and at least three independent experiments for (E-G). P by two tailed t-test.
(H) GDF15 protein in supernatant of mouse derived 2D duodenal organoids treated with metformin in the absence or presence of ISRIB (1 M). Data is expressed as mean ± SEM from two independent experiments, P by 2 way ANOVA with Sidak's correction for multiple comparisons.
(I) GDF15 protein in supernatants of mouse-derived 2D duodenal organoids from wild type and CHOP null mice treated with metformin from two independent experiments. Data are mean ± SEM, P by two-tailed t-test. 
